Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 Post published:January 20, 2023 Post category:Press Release
Revive Therapeutics legt aktualisiertes Informationspaket zur Unterstützung der bevorstehenden Sitzung des Typs C vor, die von der FDA für die geänderte Prüfplanvereinbarung der klinischen Phase-III-Studie für Bucillamin zur Behandlung von COVID-19 genehmigt wurde Post published:January 15, 2023 Post category:Press Release
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 Post published:January 5, 2023 Post category:Press Release
Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 Post published:December 24, 2022 Post category:Press Release
Revive Therapeutics Ltd. Expands Life Offering to Quebec Post published:December 15, 2022 Post category:Press Release
Revive Therapeutics Ltd. Announces Offering of Up to $5 Million Post published:December 1, 2022 Post category:Press Release
Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA Post published:October 15, 2022 Post category:Press Release
Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program Post published:September 16, 2022 Post category:Press Release
Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA Post published:September 14, 2022 Post category:Press Release
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Post published:June 6, 2022 Post category:Press Release